Genentech reports Phase III GOYA study results of Gazyva

Genentech has reported that the Phase III GOYA study evaluating Gazyva (obinutuzumab) and CHOP chemotherapy (G-CHOP) in patients with earlier untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news